19940620
 Glaxo's ulcer drug faces patent fight from Novopharm   By Moore, Stephen D, The Wall Street Journal,  Jun 21, 1994  Glaxo Holdings PLC's Zantac ulcer drug is about to face another generic challenge because Novopharm Ltd of Canada has applied with the FDA for approval of a generic version of Zantac's active ingredient, ranitidine hydrochloride. Glaxo will likely sue Novopharm for alleged patent infringement.   
